Advances in Precision Editing Therapies for Alpha-1 Antitrypsin Deficiency
Human Gene Therapy · 2026
DOI: 10.1177/10430342261417356 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Jenny Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency, Genetic Therapy, Gene Editing, alpha 1-Antitrypsin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Genome and RNA editing modalities have revolutionized precision gene therapy, offering a safer alternative to traditional gene replacement approaches. Alpha-1 antitrypsin deficiency (AATD) is a compelling model for precision medicine because the disease mechanism is well defined—mutations in a single gene are responsible for both liver and lung pathology. In this review, we summarize the current preclinical and clinical efforts for AATD, with an emphasis on genome and RNA editing strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Department of Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Li Weibo Institute for Rare Diseases Research, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Department of Pediatrics, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Gao, J., Sontheimer, E., Flotte, T. R., & Xue, W. (2026). Advances in Precision Editing Therapies for Alpha-1 Antitrypsin Deficiency. Human Gene Therapy. https://doi.org/10.1177/10430342261417356
Vancouver
Gao J, Sontheimer E, Flotte TR, Xue W. Advances in Precision Editing Therapies for Alpha-1 Antitrypsin Deficiency. Human Gene Therapy. 2026. doi:10.1177/10430342261417356
BibTeX
@article{Gao2026,
author = {Gao, Jenny and Sontheimer, Erik and Flotte, Terence R and Xue, Wen},
title = {Advances in Precision Editing Therapies for Alpha-1 Antitrypsin Deficiency},
journal = {Human Gene Therapy},
year = {2026},
doi = {10.1177/10430342261417356}
}
EUVIMED